Protocol for Electrophoretic Mobility Shift Assay (EMSA)

Reagents and chemicals

• Use nuclear extract, whole-cell extract, or purified recombinant protein as the protein source; nuclear extracts are commonly used for transcription-factor EMSA because many active DNA-binding proteins are nuclear^[2][5].

• Use a double-stranded DNA oligonucleotide probe containing the candidate binding site, or an RNA probe when testing RNA-protein binding; label the probe with ^32P, fluorescent dye, DIG, or biotin only when the detection method is validated for the assay^[1][2][6][7].

• Use nonspecific competitor DNA such as poly(dI-dC) to reduce nonspecific DNA binding in crude extracts, and use unlabeled wild-type, mutant, or unrelated competitor oligonucleotides to test sequence specificity^[3][5].

Antibodies, probes, dyes, or kits

• Use antibodies against the candidate DNA-binding protein for supershift EMSA, where antibody binding causes further retardation or loss of the shifted complex^[2][3][4].

• Use fluorescently labeled probes and infrared or fluorescence scanners as a nonradioactive alternative to radiolabeled EMSA when sensitivity and signal range are validated^[6][7].

Cells, tissues, isolated organs, organoids, or animals

• Use cancer cells, primary neurons, tumor tissue, organoid-derived cells, or macrophages only as sources of protein extract for EMSA; matched untreated, stimulated, vehicle-treated, or drug-treated samples should be prepared in parallel when comparing signaling or drug effects^[2][5].

Buffers and solutions

• Prepare extract buffer, binding buffer, native gel buffer, loading buffer without denaturants, and electrophoresis buffer; maintain native conditions because protein-nucleic acid complex stability and mobility depend on buffer composition, salt, temperature, and gel conditions^[1][2].

Equipment and instruments

• Use refrigerated centrifuge, gel casting equipment, native polyacrylamide electrophoresis apparatus, power supply, gel dryer for radioactive EMSA, phosphorimager or autoradiography system, or fluorescence/chemiluminescence imaging system depending on probe label^[1][2][6].

Controls

• Include free probe alone, extract alone when compatible with the detection format, positive-control extract or protein, no-protein control, unlabeled wild-type competitor, mutant competitor, unrelated competitor, and antibody supershift control^[2][3][4].

Preparation Steps

• Prepare protein extracts from the selected biological model under conditions that preserve DNA- or RNA-binding activity, quantify protein concentration, and keep extraction conditions consistent across experimental groups^[2][5].
• Design a probe containing the candidate binding site and a matched mutant probe or mutant competitor; for allele-specific or variant-specific EMSA, compare risk and non-risk or wild-type and mutant oligonucleotides under the same binding conditions^[3][8].
• Cast or prepare a native polyacrylamide gel appropriate for separating free probe from protein-probe complexes; EMSA is performed under non-denaturing conditions because denaturing gels disrupt protein-nucleic acid complexes^[1][2].

Operation Steps

• Preincubate protein extract with binding buffer and nonspecific competitor DNA before adding labeled probe when using crude nuclear extract, because omission of preincubation with competitor DNA can produce nonspecific Ku-dependent bands^[5].
• Add labeled probe to the binding reaction and incubate under validated conditions that preserve the complex; exact protein amount, probe amount, time, temperature, salt, and competitor concentration should be optimized and reported because EMSA complex stability is system-dependent^[1][2].
• For competition EMSA, add excess unlabeled wild-type competitor, mutant competitor, or unrelated competitor before or during binding; loss of shifted signal with wild-type but not mutant or unrelated competitor supports sequence-specific binding^[3][4].
• For supershift EMSA, add a specific antibody against the candidate protein to the binding reaction and compare mobility with no-antibody and irrelevant-antibody controls; a slower supershifted complex or disappearance of the original complex supports protein identity^[2][3][4].
• Load reactions onto a native gel and electrophorese under non-denaturing conditions until free probe and shifted complexes are resolved^[1][2].
• Detect the labeled probe by autoradiography, phosphorimaging, fluorescence scanning, DIG-based detection, or biotin-based chemiluminescence according to the probe label^[2][6][7][9].

Data Acquisition and Analysis

• Acquire images within the linear range of detection and quantify free probe, shifted complex, supershifted complex, and competition-dependent signal reduction by densitometry or phosphorimager/fluorescence signal analysis^[1][2].
• Normalize shifted-band intensity to total probe signal per lane or to a matched positive-control lane, and compare only samples run under identical binding, gel, and exposure conditions^[1][2].
• Interpret increased shifted signal as increased binding activity in the extract, not necessarily increased protein abundance; confirm abundance by Western blot, localization by immunofluorescence, transcript effects by qPCR, and chromatin occupancy by ChIP-based assays when biological interpretation requires these endpoints^[2][3].
• Use independent biological extracts for comparisons across cancer cells, neurons, tumor samples, organoids, macrophages, or drug treatments, and use technical replicate binding reactions when estimating assay variability^[2][8].

Problem: Strong nonspecific shifted bands.

Possible Cause: nonspecific DNA-binding proteins such as Ku bind probe ends in crude nuclear extract.
Literature-supported Solution: preincubate extract with nonspecific competitor DNA before adding labeled probe and verify specificity with wild-type, mutant, and unrelated competitors^[5].

Problem: Shifted band does not disappear with mutant competitor.

Possible Cause: the complex is not sequence-specific for the proposed motif.
Literature-supported Solution: use wild-type, mutated, and unrelated competitor oligonucleotides; only wild-type sequence-specific competitor should reduce a specific complex^[3][4].

Problem: Protein identity is uncertain.

Possible Cause: multiple proteins or multiprotein complexes bind the same probe.
Literature-supported Solution: perform antibody supershift or EMSA coupled to immunoblotting/proteomic identification when antibody supershift is insufficient^[3][4][10].

Problem: Weak signal with nonradioactive EMSA.

Possible Cause: probe label or detection method lacks sufficient sensitivity for the complex.
Literature-supported Solution: use optimized fluorescent, DIG, biotin, or radiolabeled probe detection and validate signal sensitivity against a positive-control binding reaction^[2][6][7][9].

Problem: Drug-treated samples show reduced binding.

Possible Cause: true inhibition of binding, reduced protein abundance, extract toxicity, or poor nuclear extraction.
Literature-supported Solution: compare with vehicle control and confirm protein abundance or nuclear localization using orthogonal assays such as Western blot or immunofluorescence^[2][3].